CL2012002560A1 - Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). - Google Patents

Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).

Info

Publication number
CL2012002560A1
CL2012002560A1 CL2012002560A CL2012002560A CL2012002560A1 CL 2012002560 A1 CL2012002560 A1 CL 2012002560A1 CL 2012002560 A CL2012002560 A CL 2012002560A CL 2012002560 A CL2012002560 A CL 2012002560A CL 2012002560 A1 CL2012002560 A1 CL 2012002560A1
Authority
CL
Chile
Prior art keywords
nle3
peptide
amino acids
contiguous amino
hec
Prior art date
Application number
CL2012002560A
Other languages
English (en)
Inventor
Kathleen E Rodgers
Gere S Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45571822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002560(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of CL2012002560A1 publication Critical patent/CL2012002560A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para el tratamiento de úlceras de pie diabético que comprende un péptido de al menos 5 aminoácidos contiguos de NLE3 a(1-7) efectivo; formulación farmacéutica que comprende hidroxietil celulosa (HEC) y un péptido de al menos 5 aminoácidos contiguos de NLE3 A(1-7).
CL2012002560A 2011-02-02 2012-09-14 Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7). CL2012002560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438780P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
CL2012002560A1 true CL2012002560A1 (es) 2013-03-22

Family

ID=45571822

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002560A CL2012002560A1 (es) 2011-02-02 2012-09-14 Metodos para el tratamiento de ulceras de pie diabetico que comprende un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7) efectivo; formulacion farmacéutica que comprende hidroxietil celulosa (hec) y un peptido de al menos 5 aminoacidos contiguos de nle3 a(1-7).

Country Status (20)

Country Link
US (3) US8207233B1 (es)
EP (1) EP2536422B8 (es)
JP (2) JP5469777B2 (es)
KR (1) KR101514414B1 (es)
CN (1) CN102858360B (es)
AU (1) AU2012212220B2 (es)
BR (1) BR112013019513A2 (es)
CA (1) CA2793515C (es)
CL (1) CL2012002560A1 (es)
CO (1) CO6592101A2 (es)
DK (1) DK2536422T3 (es)
EA (1) EA026440B1 (es)
ES (1) ES2479765T3 (es)
MX (1) MX2012010783A (es)
PE (1) PE20130379A1 (es)
PL (1) PL2536422T3 (es)
PT (1) PT2536422E (es)
SG (1) SG183960A1 (es)
WO (1) WO2012106427A2 (es)
ZA (1) ZA201207340B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2536422B8 (en) * 2011-02-02 2023-06-21 University of Southern California Methods for treating diabetic foot ulcers
EP2849773A1 (en) 2012-05-14 2015-03-25 University of Southern California Methods for limiting development of a skin wound
US20150246093A1 (en) * 2012-09-17 2015-09-03 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US9289500B2 (en) * 2013-02-22 2016-03-22 The Regents Of The University Of California Saccharide-peptide hydrogels
AU2014233185B2 (en) 2013-03-15 2018-03-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP2968441A1 (en) 2013-03-15 2016-01-20 University of Southern California Methods for treating multiple sclerosis
WO2015138288A1 (en) * 2014-03-10 2015-09-17 Rush University Medical Center Methods of promotion of healing of diabetic wounds
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
US20180344680A1 (en) * 2015-12-08 2018-12-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
WO2021072225A1 (en) * 2019-10-09 2021-04-15 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
DE69435301D1 (de) 1993-09-24 2010-08-26 Univ Southern California Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
ES2168312T3 (es) 1993-09-24 2002-06-16 Univ Southern California Utilizacion de angiotensina iii y sus analogos para la reparacion tisular.
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU6650098A (en) 1997-02-04 1998-08-25 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
CA2315266C (en) 1997-12-12 2004-08-10 University Of Southern California Wound healing compositions
CA2321168A1 (en) 1998-02-09 1999-08-12 University Of Southern California Method of promoting keratinocyte proliferation
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
AU3077299A (en) 1998-03-11 1999-09-27 University Of Southern California Method of promoting production of living tissue equivalents
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU759285B2 (en) 1998-05-11 2003-04-10 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
DE69911609T2 (de) 1998-07-13 2004-07-01 University Of Southern California, Los Angeles Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel
AU755943B2 (en) 1998-08-13 2003-01-02 University Of Southern California Methods to increase blood flow to ischemic tissue
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
WO2001044270A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
EP1292610A1 (en) * 2000-06-19 2003-03-19 University Of Southern California Methods for treating and preventing alopecia
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
CN102905719B (zh) 2010-03-26 2015-04-22 南加利福尼亚大学 治疗复合性辐射和热损伤的方法
WO2012021578A1 (en) 2010-08-10 2012-02-16 University Of Southern California Use of angiotensin- ii (1-7) in cell trans planation and as an agent for preventing/treating norovirus infection
EP2536422B8 (en) * 2011-02-02 2023-06-21 University of Southern California Methods for treating diabetic foot ulcers

Also Published As

Publication number Publication date
BR112013019513A2 (pt) 2019-06-11
WO2012106427A2 (en) 2012-08-09
AU2012212220A1 (en) 2012-10-18
EP2536422A2 (en) 2012-12-26
KR20120137365A (ko) 2012-12-20
JP2013523781A (ja) 2013-06-17
CN102858360A (zh) 2013-01-02
MX2012010783A (es) 2012-11-23
EA026440B1 (ru) 2017-04-28
CA2793515C (en) 2015-05-12
KR101514414B1 (ko) 2015-05-04
SG183960A1 (en) 2012-10-30
US8536231B2 (en) 2013-09-17
ZA201207340B (en) 2013-02-27
JP2014080425A (ja) 2014-05-08
HK1180213A1 (en) 2013-10-18
EP2536422B1 (en) 2014-04-30
CN102858360B (zh) 2017-07-25
DK2536422T3 (da) 2014-07-28
PT2536422E (pt) 2014-07-18
US20120329729A1 (en) 2012-12-27
PE20130379A1 (es) 2013-04-13
EA201201296A1 (ru) 2013-02-28
AU2012212220B2 (en) 2013-04-04
US8207234B1 (en) 2012-06-26
PL2536422T3 (pl) 2014-09-30
CA2793515A1 (en) 2012-08-09
JP5469777B2 (ja) 2014-04-16
EP2536422B8 (en) 2023-06-21
US8207233B1 (en) 2012-06-26
CO6592101A2 (es) 2013-01-02
WO2012106427A3 (en) 2012-09-20
ES2479765T3 (es) 2014-07-24

Similar Documents

Publication Publication Date Title
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
CR20130259A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
BR112013031268A8 (pt) polipeptídeos
PE20140255A1 (es) Tableta dispersable en forma oral
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
BR112012017691A2 (pt) nova composição
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
ECSP13012603A (es) Nueva formulacion del cetp(1)
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
NI201200196A (es) Agentes terapéuticos 976
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad
CL2008003711A1 (es) Proceso para preparar una forma de dosificación farmaceutica que comprende florfenicol o un análogo de este; y para recuperar florfenicol o un análogo de una composición farmacéutica.